Table 2 Risk of outcomes associated with switchers vs. non-switchers in patients with cancer-associated venous thrombosis

From: Effectiveness and safety of continuous low-molecular-weight heparin versus switching to direct oral anticoagulants in cancer-associated venous thrombosis

 

Events/Incidence (per 100 person-year)

Unweighted

Weighted

Competing Risk

 

Non-switchers (N = 2656)

Switchers (N = 1700)

Hazard ratio (95% CI)

P value

Hazard ratio (95% CI)

P value

Sub-distribution hazard ratio (95% CI)

P value

Hospitalization due to VTE

148/21

53/10

0.48 (0.35-0.65)

3.73e-6

0.49 (0.35-0.68)

1.61e-5

0.58 (0.42-0.80)

7.70e-4

 Hospitalization due to DVT

99/14

28/5

0.38 (0.25-0.58)

5.73e-6

0.40 (0.26-0.61)

3.01e-5

0.49 (0.32-0.74)

7.20e-4

 Hospitalization due to PE

52/7

26/5

0.68 (0.42-1.08)

0.104

0.67 (0.41-1.09)

0.108

0.75 (0.46-1.25)

0.280

Major bleeding

192/27

139/26

1.01 (0.81-1.26)

0.931

1.04 (0.83-1.31)

0.724

1.18 (0.94-1.48)

0.150

 ICH

24/3

11/2

0.63 (0.31-1.29)

0.205

0.63 (0.30-1.32)

0.223

0.72 (0.35-1.51)

0.390

 GI bleeding

48/6

41/7

1.17 (0.77-1.78)

0.458

1.23 (0.80-1.90)

0.338

1.43 (0.93-2.19)

0.100

 Bleeding of other critical sites

122/17

89/16

1.02 (0.78-1.35)

0.865

1.05 (0.79-1.40)

0.728

1.18 (0.89-1.56)

0.260

All-cause mortality

1629/216

729/129

0.61 (0.56-0.67)

6.53e-28

0.67 (0.61-0.74)

1.63e-17

-

-

  1. N Number of patients, CI Confidence interval, VTE Venous thromboembolism, DVT deep vein thrombosis, PE pulmonary embolism, ICH intracranial hemorrhage, GI bleeding gastrointestinal bleeding. All P values were from 2-sided tests and results were deemed statistically significant at P < 0.05.
Back to article page